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Anti-aggregation therapy in patients with acute 
coronary syndrome — recommendations for 
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INTRODUCTION
Cardiovascular diseases (CVD) constitute the most common 
cause of death globally, and account for 17.5 million deaths 
annually, or 31% of all deaths reported worldwide per year 
[1]. In Europe, more than 4 million patients die due to CVD 
per year, which is as much as 45% of all deaths reported 
annually in the Old Continent [2]. Among all CVD the most 
common cause of death is ischaemic heart disease (IHD), 
responsible for about 20% of all deaths reported in Europe. In 
Poland, the mortality rate for IHD is currently 191 deaths per 
100,000 inhabitants. Noteworthy is the fact that this rate has 
decreased by 39% over the last 10 years. Still, however, this 
rate is markedly lower when calculated for the entire European 
Union and equals to 132 deaths per 100,000 inhabitants, in 
some countries being even lower than 100 (France, Portugal, 
the Netherlands, Spain, Belgium, Denmark, Luxembourg, 
Greece, and Liechtenstein) [2]. In spite of the improvement 
in prognosis for patients with acute coronary syndrome (ACS), 
particularly with myocardial infarction (MI), observed in re-
cent years, this form of IHD is still associated with high risk 
of death. In our country the total in-hospital mortality rate 
among patients with MI is about 11% (6% for patients man-
aged invasively vs. 18–24% for patients receiving conservative 
treatment), while the mortality rate in the first 12 months 
after MI is up to 19% [3]. It should be noted that despite the 
major reduction in the in-hospital mortality rate, pre-hospital 
mortality remains relatively high.
Due to different management strategies applied in pa-
tients with ACS, MI is commonly classified as ST-elevation 
MI (STEMI) or non-ST-elevation ACS (NSTE-ACS). Of note, 
the epidemiology of ACS in Poland over the recent years has 
displayed some steady trends of changes. In 2009, 59% of all 
patients with MI were those with STEMI, while in 2012 this 
rate decreased to 48% [3]. In 2014, patients with STEMI ac-
counted for 33% of all ACS patients treated with percutaneous 
coronary intervention (PCI), while patients with non-STEMI 
(NSTEMI) and unstable angina (UA) accounted for 28% and 
39%, respectively [4].
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Activation and aggregation of platelets play a key role in 
the pathophysiology of ACS, including MI [5, 6]. Injury of an 
atherosclerotic plaque results in intraluminal exposure of ele-
ments of the extracellular matrix, such as collagen, von Wille-
brand factor, fibronectin, or laminin. Contact of the platelets 
with these molecules triggers platelet activation, which starts 
the cascade of events leading to thrombus formation [7–10]. 
Activated platelets release active substances stored in their 
dense granularities, i.a. adenosine diphosphate (ADP), which 
is the main agonist of the platelet P2Y12 receptor [11, 12].
Activation of the platelet P2Y12 receptor by ADP plays 
a pivotal role in sustaining platelet activation and stabilisation 
of platelet aggregates. These processes lead to formation of 
a platelet-rich thrombus at the site of damage of the wall 
of a coronary artery, with resulting impairment of coronary 
blood flow and reduced oxygen supply to cardiomyocytes 
[13]. The most common clinical manifestation of myocardial 
ischaemia is ACS-specific chest pain. Other possible clinical 
presentations of ACS include i.a.: dyspnoea, abdominal pain, 
nausea/vomiting, general weakness, loss of consciousness, 
or sudden cardiac death. Prolonged myocardial ischaemia 
ultimately results in necrosis of myocardial cells and develop-
ment of MI [5]. The multidimensional impact of P2Y12 recep-
tor activation on the processes associated with formation of 
thrombi within the lumen of coronary arteries is the reason 
why this receptor has become one of the main targets of 
antiplatelet therapy.
ANTI-AGGREGATION TREATMENT IN PATIENTS 
WITH ACS IN POLAND
Nowadays the role of medical emergency team members is 
not only to quickly establish the preliminary diagnosis or to 
secure efficient transport of an ACS patient to hospital, but 
also, equally importantly, to initiate the treatment of ACS 
patients, particularly by starting antiplatelet therapy.
Restriction of excess platelet activation and inhibition of 
platelet aggregation with dual antiplatelet therapy (DAPT), 
including acetylsalicylic acid (ASA) and one of the P2Y12 re-
ceptor inhibitors, is already a standard of care in patients 
with ACS [14–16].
There are recommendations, developed by experts 
commissioned by international scientific societies, address-
ing optimal therapeutic management strategies for patients 
with ACS, including the strategy for use of DAPT. Continuous 
progress in medical knowledge, and the specific situation in 
our country with respect to drug availability and organisation 
of the system of medical emergency service and hospital care, 
warrant presentation of a standpoint concerning the clinical 
practice used to date.
The principles of the antiplatelet therapy currently used in 
Poland in ACS patients are based on the following three docu-
ments: the guidelines of the European Society of Cardiology 
(ESC) on the management of STEMI published in 2012; guide-
lines of the ESC and European Association for Cardio-Thoracic 
Surgery (EACTS) on myocardial revascularisation published in 
2014; and guidelines of the ESC on management of NSTE-ACS 
published in 2015 [14–16]. The guidelines of ESC concerning 
use of DAPT in patients with ACS were confirmed, although 
much less precisely, in the guidelines of the European Resus-
citation Council (ERC) published in 2015 [17].
ACETYLSALICYLIC ACID THERAPY  
IN PATIENTS WITH ACS
Acetylsalicylic acid is an irreversible inhibitor of platelet cy-
clooxygenase isoenzyme type 1 (COX-1). According to the cur-
rent guidelines, administration of an oral, rapidly absorbed ASA 
formulation in a loading dose of 150–300 mg is recommended 
in all ACS patients with no contraindications and no history of 
prior chronic use of ASA. When oral intake is not possible, ASA 
can be administered intravenously in the dose of 75–150 mg, 
however the i.v. formulation of ASA is not available in Poland. 
Quite often ASA is administered in the pre-hospital period. 
According to the current guidelines, in patients with STEMI, 
treatment should be applied as early as possible, i.e. upon the 
first medical contact. Then, all patients should receive chronic 
therapy with ASA 75–100 mg q.d. — class of recommendation 
I, level of evidence A [14–16]. Increasing the dose above that 
level not only does not improve treatment efficacy, but also 
increases the risk of bleeding [18–20].
PLATELET P2Y12 RECEPTOR INHIBITORS
The current recommendations concerning the treatment of 
patients with ACS emphasise the need to use DAPT, including 
ASA and a platelet P2Y12 receptor inhibitor, for 12 months 
following ACS, unless contraindicated due to excessive risk of 
bleeding — class of recommendation I, level of evidence A. 
This recommendation is valid for patients both with STEMI 
and NSTE-ACS [15, 16].
Currently, the oral platelet P2Y12 inhibitors available in 
Poland are: clopidogrel, prasugrel, and ticagrelor. A registered, 
but still unavailable medication of this group is cangrelor 
— a compound designed for intravenous use only. Clopidogrel 
and prasugrel are pro-drugs and require activation in the liver 
into active metabolites irreversibly blocking the P2Y12 recep-
tor, whereas ticagrelor and cangrelor are active drugs, which 
directly and reversibly block this receptor (Table 1) [16].
The guidelines preferentially recommend the newer 
P2Y12 inhibitors (prasugrel and ticagrelor) for their faster, more 
potent, and more uniform anti-aggregation effect translating 
into better clinical outcomes as compared with clopidogrel 
[21–25].
A clinical study entitled Trial to Assess Improvement 
in Therapeutic Outcomes by Optimising Platelet Inhibi-
tion with Prasugrel-Thrombolysis in Myocardial Infarction 
38 (TRITON-TIMI 38) demonstrated superiority of prasugrel 
over clopidogrel for reduction of composite ischaemic end-
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point [26]. Repeated ischaemic cardiovascular events were less 
frequent (9.3% vs. 11.2%; p = 0.002), whereas severe haem-
orrhagic complications were more frequent (2.4% vs. 1.8%; 
p = 0.03) in patients treated with prasugrel, as compared with 
those receiving clopidogrel [26]. Particularly great benefits of 
treatment with prasugrel, with no increase in bleeding risk, 
are observed in patients with ACS and diabetes mellitus [27].
Another clinical study, entitled Platelet Inhibition and 
Patient Outcomes (PLATO), conducted in patients with 
ACS, demonstrated better outcomes of treatment with 
ticagrelor vs. clopidogrel with respect to reduction in the 
rates of composite ischaemic endpoint (9.8% vs. 11.7%; 
p < 0.001) and cardiovascular mortality (4.0% vs. 5.1%; 
p = 0.001) [28], with no concomitant increase in the risk 
of severe bleeding.
When starting treatment with P2Y12 inhibitors one should 
always be aware of contraindications for these drugs. Prasugrel 
is contraindicated in patients with a history of intracranial 
haemorrhage, ischaemic cerebral stroke or transient ischae-
mic attacks, or with active bleeding. Prasugrel is generally 
not recommended for patients above 75 years of age or with 
body weight below 60 kg. Also, ticagrelor is contraindicated 
in patients with a history of intracranial haemorrhage or with 
active bleeding. Moreover, both prasugrel and ticagrelor are 
not recommended for use in dialysis patients and in those 
requiring chronic oral anticoagulation (Table 2).
It should be emphasised that clopidogrel is the only 
P2Y12 inhibitor to be used in combination with oral antico-
agulants (acenocoumarol, apixaban, dabigatran, rivaroxaban, 
or warfarin). Use of ticagrelor or prasugrel as part of triple 
therapy is not recommended — class of recommendation III, 
level of evidence C [15].
Platelet P2Y12 receptor inhibitors in  
the treatment of patients with STEMI
Detection of persistent ST elevation in two neighbouring 
electrocardiogram (ECG) leads in a patient with stenocardial 
complaints substantiates the preliminary diagnosis of STEMI. 
Table 1. Comparison of P2Y12 receptor inhibitors recommended by the European Society of Cardiology
  clopidogrel prasugrel ticagrelor cangrelor
Chemical class Thienopyridine Thienopyridine Cyclopentyl-triazolo- 
-pyrimidine
ATP analogue
Administration route Oral Oral Oral Intravenous
Standard dosing:
   Loading dose 300 or 600 mg 60 mg 180 mg 30 μg/kg bolus
   Maintenance dose 1 × 75 mg or 
1 × 150 mg
1 × 10 mg or 
1 × 5 mg
2 × 90 mg 4 μg/kg/min  
infusion
Prodrug Yes Yes No No
P2Y12 receptor binding Irreversible Irreversible Reversible Reversible
Onset of antiplatelet effect 2–6 h# 30 min# 30 min# 2 min
Offset of antiplatelet effect 3–10 days 5–10 days 3–4 days 1–2 h
Recommended withdrawal before surgery 5 days 7 days 5 days 1 h
#Data from healthy volunteers and patients with stable coronary disease. In patients with acute coronary syndromes the onset of action is  
probably delayed; ATP — adenosine triphosphate
Table 2. Contraindications to use of oral P2Y12 receptor antagonists
Contraindication clopidogrel prasugrel ticagrelor
Active bleeding
Severe liver disorders
History of ischaemic stroke Within 7 days
History of TIA
History of intracranial haemorrhage
Use of oral anticoagulants
Age ≥ 75 years
Body weight < 60 kg
TIA — transient ischaemic attack; blue — can be used; grey — is not recommended; black — should not be used
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STEMI is most commonly caused by total occlusion of a coro-
nary artery, which results in progressive necrosis of myocardial 
cells. This implies the necessity to restore patency of the 
occluded artery as soon as possible. The preferred method 
of coronary revascularisation is PCI [14, 16]. The ESC guide-
lines emphasise that pre-hospital management of patients 
with STEMI must be based on regional networks designed 
to secure quick and effective reperfusion therapy. Mobile 
medical emergency teams must be trained and equipped 
appropriately to be able to diagnose STEMI (also employing 
ECG teletransmission systems) and initiate early treatment, if 
indicated [14].
In STEMI patients it is recommended to administer 
a P2Y12 inhibitor at first contact with the healthcare system 
— class of recommendation I, level of evidence B [16]. Al-
though this approach appears to be justified, currently there 
are no randomised clinical trials demonstrating clear clinical 
benefits of this treatment strategy [29]. Simultaneously, admin-
istration of oral P2Y12 inhibitors in pre-hospital management 
of patients with STEMI is considered to be safe [29].
For patients with STEMI the preferred P2Y12 inhibitors are 
prasugrel (administered at an initial loading dose of 60 mg, un-
less contraindicated, and at a maintenance dose of 10 mg q.d.) 
and ticagrelor (at an initial loading dose of 180 mg, unless 
contraindicated, and at a maintenance dose of 90 mg b.i.d.) 
— both equally recommended for patients with STEMI 
— class of recommendation I, level of evidence B [14, 16]. 
As mentioned earlier, when prasugrel or ticagrelor are 
unavailable or contraindicated, a loading dose of clopidogrel 
(600 mg) should be administered [14, 16]. It should be noted 
that patients who have already received a loading dose of 
clopidogrel may have their antiplatelet therapy modified 
and ticagrelor can be administered [28], which is not recom-
mended for prasugrel.
Based on theoretical evidence derived from pharma-
cokinetic and pharmacodynamic properties as well as on the 
results of clinical studies, cangrelor appears to be the optimal 
P2Y12 inhibitor for ACS patients requiring urgent invasive 
treatment. Unfortunately, this compound is still commercially 
unavailable [30, 31]. Moreover, studies to evaluate the efficacy 
and safety of cangrelor in the pre-hospital management period 
have not been conducted to date. Cangrelor may potentially 
be of particular benefit in unconscious patients, patients with 
post-cardiac arrest syndrome, or patients treated with mild 
therapeutic hypothermia, when gastrointestinal absorption of 
medications is impaired [32, 33].
In accordance with the ESC guidelines, it is a common 
practice in our country to initiate antiplatelet therapy in pa-
tients suspected of STEMI as early as at the stage of pre-hospital 
management, in the ambulance, after verification of the 
initial diagnosis by a cardiologist based on teletransmission 
of the patient’s ECG. Patients receiving antiplatelet therapy 
in this period usually receive a loading dose of clopidogrel, 
rather than prasugrel or ticagrelor. According to the current 
guidelines, this treatment strategy is not optimal; however, 
it is acceptable when prasugrel or ticagrelor are unavailable 
or contraindicated.
Platelet P2Y12 receptor inhibitors in  
the treatment of patients with NSTE-ACS
The clinical forms of NSTE-ACS include NSTEMI and UA. In 
patients with NSTEMI necrosis of cardiomyocytes develops 
secondary to myocardial ischaemia, whereas in the case of UA 
myocardial ischaemia occurs without resulting loss of cardiac 
muscle cells. Differential diagnosis between NSTEMI and UA 
is based on measurements of the levels of myocardial necrosis 
markers, mainly troponin I or T [15].
While possibly quick initiation of antiplatelet therapy and 
urgent coronary reperfusion are recommended for patients 
with STEMI, in patients with NSTE-ACS the indications and 
recommended timeframes for diagnostics and potential in-
vasive treatment depend primarily on risk stratification based 
on the patient’s clinical history, leading signs and symptoms, 
vital parameters, other signs and symptoms, as well as results 
of ECG and laboratory tests. Therefore, only some patients 
with NSTE-ACS (very high risk patients) require urgent (within 
2 h) coronary angiography and usually PCI. The urgent ap-
proach is indicated in the presence of at least one of the 
following factors:
 — unstable haemodynamic condition or cardiogenic shock;
 — recurrent or sustained chest pain resistant to conserva-
tive treatment;
 — life-threatening cardiac arrhythmia or cardiac arrest;
 — mechanical complications of ACS;
 — acute heart failure;
 — recurrent dynamic changes of ST-T segment, especially 
with transient ST elevation [15].
Similar to STEMI, a 12-month course of DAPT, including 
ASA and one of the P2Y12 inhibitors, is also recommended 
in patients with NSTE-ACS, unless contraindicated, e.g. due 
to excessive risk of bleeding [15]. The guidelines concerning 
treatment of NSTE-ACS contain information that therapy with 
P2Y12 inhibitors should be instituted immediately after estab-
lishing the diagnosis of NSTE-ACS, regardless of the manage-
ment strategy. Unfortunately, that document does not provide 
more precise recommendations concerning the optimal time 
of initiation of antiplatelet therapy in such patients. In this 
group of patients the preferred P2Y12 inhibitors are prasu-
grel and ticagrelor, with equal recommendations — class of 
recommendation I, level of evidence B [15].
For NSTE-ACS prasugrel is recommended in patients 
qualified for PCI. Simultaneously, its early administration is 
discouraged in patients with unknown anatomy of the coro-
nary arteries — class of recommendation III, level of evidence 
B [15]. Respecting both of these recommendations means that 
patients with NSTE-ACS should not be given prasugrel prior 
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rate, and absorption and efficacy of oral P2Y12 inhibitors 
[38, 40–45].
As there is no effective alternative to morphine in anal-
getic management of patients with ACS, this drug has been 
reappearing in subsequent editions of ESC guidelines. In 
patients with STEMI with pronounced-to-severe chest pain 
graded intravenous dosing of morphine is recommended 
for reduction of pain complaints — class of recommenda-
tion I, level of evidence C [14]. The most recent guidelines 
concerning the management of NSTE-ACS provide no official 
recommendation for the use of morphine in that group of 
patients. The authors confirm, however, that administration 
of opioids is reasonable when the patient is waiting for urgent 
coronary angiography, with morphine or alternative opioids 
reserved for patients with sustained severe chest pain [15]. It 
should be noted that these recommendations are not based 
on the results of randomised clinical trials, but on experts’ 
opinion only.
Considering the current knowledge, routine withdrawal 
from morphine use in ACS patients cannot be recommended. 
It seems reasonable, however, to reserve this treatment only 
for those patients who report severe chest pain or present 
with signs of acute heart failure (e.g. resting dyspnoea) [46]. 
It also appears justified to use the minimal effective dose with 
a view to limit the adverse effects of morphine.
COMMENT
It should be emphemphasised that clopidogrel, which is still 
commonly used in our country, according to current guidelines 
is not the first-choice P2Y12 inhibitor in patients with ACS 
any more. For these patients, ESC guidelines clearly recom-
mend use of ticagrelor or prasugrel as preferred P2Y12 block-
ers. Contrary to prasugrel, ticagrelor is recommended for all 
patients with STEMI and NSTE-ACS, regardless of management 
strategy, including patients on conservative treatment and 
those who had already received clopidogrel previously. Prasu-
grel, in turn, is recommended in patients with STEMI, and 
exclusively in NSTE-ACS patients who have been qualified for 
PCI based on the results of coronary angiography. According 
to current ESC guidelines, use of clopidogrel in patients with 
STEMI or NSTE-ACS should be limited to situations when both 
ticagrelor and prasugrel are unavailable or contraindicated 
— class of recommendation I, level of evidence B [15, 16].
We should remember, however, about a distinctive group 
of ACS patients who otherwise require anticoagulant therapy, 
e.g. due to atrial fibrillation, since they should be treated with 
clopidogrel rather than prasugrel or ticagrelor. Therefore, it is 
very important to correctly assess the patient for the presence 
of potential contraindications prior to initiation of treatment 
with an oral P2Y12 inhibitor.
Another important subgroup of ACS patients are those 
who — following diagnostic coronary angiography — be-
come candidates for urgent coronary artery bypass grafting 
to coronary angiography or when qualified for conservative 
treatment. In practice, these limitations preclude pre-hospital 
use of prasugrel in NSTE-ACS patients.
For NSTE-ACS, a ticagrelor loading dose of 180 mg fol-
lowed by 90 mg b.i.d. is recommended in all patients with 
moderate and high risk of ischaemic events, regardless of 
the initial management strategy, unless contraindicated. It 
is important to note that this recommendation also includes 
patients who had received clopidogrel previously (in case 
of which clopidogrel should be discontinued at the time of 
initiation of ticagrelor treatment). This means that ticagrelor 
can be used also in those NSTE-ACS patients who are not 
candidates for prasugrel, i.e. in patients on conservative treat-
ment, prior to coronary angiography, and in those who had 
received a loading dose of clopidogrel [15].
A clopidogrel loading dose of 300–600 mg followed 
by 75 mg q.d. is recommended in patients with NSTE-ACS, 
who cannot receive ticagrelor and prasugrel or require oral 
anticoagulant therapy — class of recommendation I, level of 
evidence B [15].
ANALGETIC TREATMENT
Morphine is the primary analgetic drug used in patients with 
ACS, particularly in those with MI. In addition to potent an-
algetic action, this opioid also has tranquillising and euphoric 
effects. Effective reduction of the severity of chest pain and 
sedation of the patient result in a decrease of arterial blood 
pressure and heart rate, which improves myocardial oxygen 
demand/delivery ratio [34]. Due to its potential positive effect 
on the pathophysiology of ACS, high efficacy in symptomatic 
management of chest pain, wide availability, and long-term 
experience of clinical use, morphine is commonly used in 
ACS patients. Morphine is frequently administered in patients 
with ACS already at the pre-hospital stage, with the intention 
to reduce pain during transport to hospital before causative 
therapy is initiated.
However, use of morphine quite commonly produces 
adverse effects, such as bradycardia, arterial hypotension, 
and impairment of the intestinal propulsive function, and 
sometimes also suppression of respiratory function [35]. 
The influence of morphine on the gastrointestinal tract and 
central nervous system may lead to vomiting and decelera-
tion of intestinal transit, which may result in impaired and 
delayed absorption of oral medications, including DAPT [35]. 
In the event of respiratory depression following morphine 
administration, this effect may be reverted with intravenous 
naloxone (usually a single dose of 0.4–2 mg, repeated doses 
every 2–3 min, if needed) [36].
Currently there are no randomised clinical studies to 
evaluate the safety of morphine in patients with ACS, and the 
data from registries are equivocal [37–39]. However, results 
of numerous clinical tests point to a possible negative effect 
of morphine on the extent of infarction, patient mortality 
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(CABG). In Poland 2% of all patients with MI undergo CABG 
during hospitalisation due to ACS [3]. Identification of pa-
tients requiring CABG is based on the results of imaging of 
the coronary arteries (coronary angiography) and therefore 
is not possible in the pre-hospital period. However, the 
fact that some patients may require urgent cardiac surgery 
shortly after establishing the diagnosis of ACS by the medi-
cal emergency team should somehow affect and define the 
pre-hospital management strategy in these cases. Wherever 
possible, direct transport of the highest risk patients (STEMI 
and NSTE-ACS of very high risk) to centres with both in-
vasive cardiology and cardiac surgery facilities should be 
considered. It should be stressed, however, that the prefer-
ence for this category of hospitals must not cause delay of 
invasive diagnostics. Long-term outcomes of treatment of 
patients with ACS undergoing urgent CABG are also affected 
by the applied antiplatelet therapy. In ACS patients treated 
with CABG, ticagrelor therapy results in reduction of risk of 
adverse cardiovascular events, including death rates, as com-
pared with clopidogrel, without increasing the risk of severe 
CABG-related bleeding [47]. In comparison with clopidogrel, 
prasugrel, the other of the two P2Y12 inhibitors preferred in 
patients with ACS, increases the risk of CABG-related bleed-
ing [26]. Therefore, when initiating antiplatelet therapy in the 
pre-hospital setting, it seems justified to prefer ticagrelor as 
the first-choice drug in patients who may potentially require 
urgent cardiac surgery.
The choice of the optimal time to start therapy with 
oral antiplatelet drugs is not supported by the results of 
the available clinical studies. Except for the results of two 
studies: Targeted Platelet Inhibition to Clarify the Optimal 
Strategy to Medically Manage Acute Coronary Syndromes 
(TRILOGY-ACS) and A Comparison of Prasugrel at PCI or 
Time of Diagnosis of Non-ST Elevation Myocardial Infarction 
(ACCOAST), which indicate lack of justification for use of 
prasugrel in patients with NSTE-ACS on conservative treat-
ment and prior to coronary angiography, there are no data 
from randomised studies defining the optimal time point for 
initiation of treatment with P2Y12 inhibitors in NSTE-ACS 
patients [48, 49]. Hence, it is difficult to formulate universal 
recommendations concerning early administration of tica-
grelor or clopidogrel for all NSTE-ACS patients [15, 50]. Still, 
however, for patients of very high risk, who require urgent 
invasive diagnostics and most commonly also PCI, it seems 
advisable to institute DAPT as soon as possible.
The data concerning the optimal period for initiation 
of antiplatelet therapy in patients with STEMI are not fully 
consistent, either. A randomised clinical study Administration 
of Ticagrelor in the Cath Lab or in the Ambulance for New 
ST Elevation Myocardial Infarction to Open the Coronary 
Artery (ATLANTIC) was conducted to evaluate the influence 
of administration of a loading dose of ticagrelor during trans-
port to hospital versus at the catheterisation lab, on cardiac 
reperfusion in 1862 patients with STEMI. No improvement 
in cardiac reperfusion before PCI was found in those study 
participants who received a pre-hospital loading dose of tica-
grelor. Importantly, no increase in the number of hemorrhagic 
complications was observed in that group. The lack of benefits 
otherwise expected in association with earlier administra-
tion of a loading dose of ticagrelor was suggested to result 
from a relatively small time difference of 31 min between its 
pre-hospital vs. in-hospital administration [51]. The fact that 
as many as 50% of the study participants received morphine is 
also likely to be responsible for the final effect. An additional 
analysis of the ATLANTIC study demonstrated that administra-
tion of a loading dose of ticagrelor in the pre-hospital setting in 
combination with PCI was associated with a lower incidence 
of ischaemic events within the first 24 h of treatment, as com-
pared with in-hospital administration of ticagrelor followed by 
PCI [52]. The results of the ATLANTIC study confirmed safety 
of ticagrelor administration in the pre-hospital setting in STEMI 
patients and provided a potent suggestion of clinical benefits 
associated with this management strategy. These results seem 
to warrant the earliest possible administration of a loading 
dose of ticagrelor by medical emergency teams when STEMI 
is diagnosed and no contraindications exist.
SUMMARY
1. Use of ECG teletransmission and teleconsultation systems 
should be part of standard management in all patients 
with suspected ACS [53]. Utilisation of the consulta-
tion options facilitates quick diagnosis of STEMI and 
NSTE-ACS, which enables early initiation of DAPT in all 
the patients who require this treatment. It also makes 
logistic management more efficient and decreases the 
time delay to revascularisation.
2. In order to make the therapeutic management of STEMI 
patients uniform, after preliminary diagnosis and tele-
consultation with a cardiologist, if no contraindications 
exist, an oral loading dose of one of the P2Y12 receptor 
inhibitors should be administered; patients with no record 
of previous intake of ASA should also be given a 300 mg 
loading dose of ASA. Due to the potential need for car-
diac surgical treatment, it is advisable in some patients 
to choose ticagrelor in a loading dose of 180 mg (Fig. 1).
3. Routine pre-hospital initiation of treatment with platelet 
P2Y12 receptor inhibitors in all patients with NSTE-ACS 
is not recommended. However, early initiation of an-
tiplatelet therapy appears advisable in patients with 
NSTE-ACS of very high risk, for whom preliminary assess-
ment indicates the need for urgent invasive treatment. 
In such cases patients with no record of previous ASA 
intake should be administered a 300 mg loading dose 
of ASA and a 180 mg loading dose of ticagrelor; when 
ticagrelor is unavailable or contraindicated, 300 mg or 
600 mg clopidogrel should be given instead (Fig. 1). It 
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should also be noted that, in accordance with the Di-
rective of the Minister of Health dated 20 April 2016, 
paramedics/emergency medical team members are al-
lowed to (after ECG teletransmission and consultation 
with the physician evaluating the ECG) administer some 
P2Y12 inhibitors, namely clopidogrel and ticagrelor, 
but not prasugrel. In the periprocedural period STEMI 
patients require antithrombotic treatment apart from 
DAPT, and, according to the above-mentioned Direc-
tive of the Minister of Health, unfractionated heparin 
(70–100 U/kg) is the only antithrombotic agent that 
can be administered by paramedics/emergency medical 
team members [54].
4. Considering the lack of consistent data, analgetic treat-
ment applied in patients with ACS during their transfer to 
hospital should be chosen and adjusted on an individual 
basis. Use of non-opioid drugs is not recommended in 
such conditions due to increased risk of bleeding when 
used simultaneously with DAPT [55]. Due to potential 
interactions with oral antiplatelet drugs, care must be 
taken when morphine and perhaps also other opioids 
are used [35]. However, analgetic treatment definitely 
cannot be denied to suffering patients, who experience 
high-intensity chest pain or dyspnoea. In such cases it 
appears reasonable to use the minimum effective dose. 
Also, when morphine is used, administration of oral 
antiplatelet drugs in crushed form may be considered, 
as it was demonstrated that crushing the tablets acceler-
ates their absorption from the gastrointestinal tract and 
shortens the time to onset of action [56–58].
5. In the pre-hospital period patients with ACS may expe-
rience vomiting with risk of loss of the yet unabsorbed 
antiplatelet drugs. In such cases the time elapsed from 
drug intake to vomiting and the potential presence of 
tablets in the vomited content should be documented. 
The decision on administration of an additional dose of 
antiplatelet drugs should be left to the discretion of the 
physician at the destination hospital.
This document was prepared on the grounds of currently 
valid guidelines and recommendations, currently available 
results of clinical studies, and theoretical assumptions, and 
is a consensus standpoint of the authors on anti-aggregation 
therapy in patients with ACS in the pre-hospital period.
Figure 1. Algorithm for pre-hospital management of patients with acute coronary syndromes; DAPT — dual antiplatelet therapy:  
preferred treatment: aspirin + ticagrelor (considering contraindications); ECG — electrocardiography; NSTE-ACS — non-ST  
elevation acute coronary syndrome; STEMI — ST-elevation myocardial infarction
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